{"id":406,"date":"2021-09-16T08:28:51","date_gmt":"2021-09-16T15:28:51","guid":{"rendered":"https:\/\/derm-biomepharmaceuticals.com\/?p=406"},"modified":"2021-09-16T08:32:30","modified_gmt":"2021-09-16T15:32:30","slug":"derm-biome-pharmaceuticals-inc-reports-positive-results-from-a-preclinical-study-in-atopic-dermatitis-its-new-generation-of-compounds-are-significantly-more-effective-than-fda-approved-topical-ad-d","status":"publish","type":"post","link":"https:\/\/derm-biomepharmaceuticals.com\/de_de_formal\/derm-biome-pharmaceuticals-inc-reports-positive-results-from-a-preclinical-study-in-atopic-dermatitis-its-new-generation-of-compounds-are-significantly-more-effective-than-fda-approved-topical-ad-d\/","title":{"rendered":"Derm-Biome Pharmaceuticals, Inc. meldet positive Ergebnisse einer pr\u00e4klinischen Studie bei atopischer Dermatitis: Seine neue Generation von Verbindungen ist deutlich wirksamer als das von der FDA zugelassene topische AD-Medikament Crisaborol"},"content":{"rendered":"<p>VANCOUVER, British Columbia, 16. September 2021 (GLOBE NEWSWIRE) \u2013 Derm-Biome Pharmaceuticals, Inc, ein in Vancouver ans\u00e4ssiges biopharmazeutisches Unternehmen, das sich auf Hautgesundheit und gesundes Altern konzentriert, freut sich bekannt zu geben, dass zwei seiner topischen Medikamente erhebliche hemmende Wirkungen hatten ein gut etabliertes Mausmodell f\u00fcr atopische Dermatitis (AD). AD ist eine chronisch entz\u00fcndliche Hauterkrankung mit erheblichem ungedecktem Bedarf, die oft mit Depressionen und einer verminderten Lebensqualit\u00e4t einhergeht. K\u00fcrzlich ver\u00f6ffentlichte Forschungsberichte gehen davon aus, dass der weltweite AD-Behandlungsmarkt bis 2026 ein Volumen von $34 Milliarden US-Dollar erreichen wird.<\/p>\n<p>Dr. Youwen Zhou, Professor f\u00fcr Dermatologie an der University of British Columbia und Direktor des Hautforschungsprogramms des Vancouver Coastal Health Research Institute: \u201eAtopische Dermatitis ist eine stark juckende entz\u00fcndliche Hauterkrankung, die bei Millionen von Menschen weltweit k\u00f6rperliches und psychisches Leiden verursacht. Die derzeit verf\u00fcgbaren Therapien, darunter das neueste von der FDA zugelassene Medikament, Crisaborol, sind aufgrund eingeschr\u00e4nkter Wirksamkeit oder Vertr\u00e4glichkeit unbefriedigend. Daher ist es spannend zu entdecken, dass mehrere der neu entwickelten Verbindungen von Derm-Biome Crisaborol bei der Blockierung der Entwicklung von Hautentz\u00fcndungen in einem Mausmodell f\u00fcr atopische Dermatitis bei weitem \u00fcbertrafen. Sollten sich weitere experimentelle Tests best\u00e4tigen, haben diese Verbindungen gro\u00dfes Potenzial, die n\u00e4chste Generation von Therapien zur Behandlung von atopischer Dermatitis zu werden.\u201c<\/p>\n<p>Diese neuartigen Verbindungen wurden in der US-Patentanmeldung mit dem Titel \u201eCOMPOSITIONS AND METHODS FOR TREATMENT OF INFLAMMATORY SKIN CONDITIONS\u201c eingereicht, die am 14. Juni 2021 eingereicht wurde.<\/p>\n<p>Gordon Eberwein, CEO von Derm-Biome: \u201eWir freuen uns sehr \u00fcber die Ergebnisse dieser Studie. Wir hatten einen vielversprechenden Medikamentenkandidaten gegen Hauterkrankungen erworben, beschlossen jedoch, eine neue Generation neuartiger Derivate zu entwickeln, in der Hoffnung, noch aktivere und l\u00f6slichere Verbindungen zu schaffen. Wir glauben nun, dass wir einen kommerziell nutzbaren Medikamentenkandidaten haben, der das Leben von Menschen verbessern wird, die an chronisch entz\u00fcndlichen Hauterkrankungen leiden.\u201c<\/p>\n<p>Dr. Poul Sorensen, CSO von Derm-Biome: \u201eWir sind absolut begeistert von den j\u00fcngsten Erkenntnissen, dass unsere Verbindungen in einem sehr gut etablierten Mausmodell f\u00fcr atopische Dermatitis hochwirksam sind.\u201c Als biomedizinischer Forscher mit langj\u00e4hrigem Interesse an molekularen Therapeutika kann ich zweifelsohne sagen, dass dramatische In-vivo-Ergebnisse dieser Art \u00e4u\u00dferst selten sind.\u201c<\/p>\n<p>Ein Antrag auf klinische Pr\u00fcfung (CTA) wird voraussichtlich bis zum ersten Quartal 2022 bei Health Canada eingereicht.<\/p>\n<p>\u00dcber Derm-Biome Pharmaceuticals, Inc<\/p>\n<p>Derm-Biome Pharmaceuticals, Inc. ist ein pr\u00e4klinisches biopharmazeutisches Unternehmen mit einer Reihe nat\u00fcrlicher Wirkstoffderivate, die sich der Verbesserung der Hautgesundheit und eines gesunden Alterns widmen. Unsere Verbindungen sind gut vertr\u00e4glich und weisen neuartige entz\u00fcndungshemmende, antimikrobielle, antioxidative und antitumorale Eigenschaften auf.<\/p>\n<p>Kontakt<br \/>\nInvestorenanfragen:<br \/>\nGordon Eberwein<br \/>\ngeberwein@derm-biome.com<br \/>\nhttps:\/\/derm-biomepharmaceuticals.com\/<\/p>","protected":false},"excerpt":{"rendered":"<p>&#8230;   <\/p>","protected":false},"author":2,"featured_media":408,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"_exactmetrics_skip_tracking":false,"_exactmetrics_sitenote_active":false,"_exactmetrics_sitenote_note":"","_exactmetrics_sitenote_category":0,"footnotes":""},"categories":[5],"tags":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v22.7 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Derm-Biome Pharmaceuticals, Inc. reports Positive Results from a Preclinical Study in Atopic Dermatitis: its new generation of compounds are significantly more effective than FDA-approved topical AD drug crisaborole - Derm-Biome Pharmaceuticals Inc.<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/derm-biomepharmaceuticals.com\/de_de_formal\/derm-biome-pharmaceuticals-inc-reports-positive-results-from-a-preclinical-study-in-atopic-dermatitis-its-new-generation-of-compounds-are-significantly-more-effective-than-fda-approved-topical-ad-d\/\" \/>\n<meta property=\"og:locale\" content=\"de_DE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Derm-Biome Pharmaceuticals, Inc. reports Positive Results from a Preclinical Study in Atopic Dermatitis: its new generation of compounds are significantly more effective than FDA-approved topical AD drug crisaborole - Derm-Biome Pharmaceuticals Inc.\" \/>\n<meta property=\"og:description\" content=\"...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/derm-biomepharmaceuticals.com\/de_de_formal\/derm-biome-pharmaceuticals-inc-reports-positive-results-from-a-preclinical-study-in-atopic-dermatitis-its-new-generation-of-compounds-are-significantly-more-effective-than-fda-approved-topical-ad-d\/\" \/>\n<meta property=\"og:site_name\" content=\"Derm-Biome Pharmaceuticals Inc.\" \/>\n<meta property=\"article:published_time\" content=\"2021-09-16T15:28:51+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-09-16T15:32:30+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/derm-biomepharmaceuticals.com\/wp-content\/uploads\/2021\/09\/announcement-2021-sept.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1000\" \/>\n\t<meta property=\"og:image:height\" content=\"539\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Derm-Biome Admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Geschrieben von\" \/>\n\t<meta name=\"twitter:data1\" content=\"Derm-Biome Admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Gesch\u00e4tzte Lesezeit\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 Minuten\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/derm-biomepharmaceuticals.com\/derm-biome-pharmaceuticals-inc-reports-positive-results-from-a-preclinical-study-in-atopic-dermatitis-its-new-generation-of-compounds-are-significantly-more-effective-than-fda-approved-topical-ad-d\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/derm-biomepharmaceuticals.com\/derm-biome-pharmaceuticals-inc-reports-positive-results-from-a-preclinical-study-in-atopic-dermatitis-its-new-generation-of-compounds-are-significantly-more-effective-than-fda-approved-topical-ad-d\/\"},\"author\":{\"name\":\"Derm-Biome Admin\",\"@id\":\"https:\/\/derm-biomepharmaceuticals.com\/#\/schema\/person\/7fd946a95040e8683129145f79976d8d\"},\"headline\":\"Derm-Biome Pharmaceuticals, Inc. reports Positive Results from a Preclinical Study in Atopic Dermatitis: its new generation of compounds are significantly more effective than FDA-approved topical AD drug crisaborole\",\"datePublished\":\"2021-09-16T15:28:51+00:00\",\"dateModified\":\"2021-09-16T15:32:30+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/derm-biomepharmaceuticals.com\/derm-biome-pharmaceuticals-inc-reports-positive-results-from-a-preclinical-study-in-atopic-dermatitis-its-new-generation-of-compounds-are-significantly-more-effective-than-fda-approved-topical-ad-d\/\"},\"wordCount\":450,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/derm-biomepharmaceuticals.com\/#organization\"},\"image\":{\"@id\":\"https:\/\/derm-biomepharmaceuticals.com\/derm-biome-pharmaceuticals-inc-reports-positive-results-from-a-preclinical-study-in-atopic-dermatitis-its-new-generation-of-compounds-are-significantly-more-effective-than-fda-approved-topical-ad-d\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/derm-biomepharmaceuticals.com\/wp-content\/uploads\/2021\/09\/announcement-2021-sept.jpg\",\"articleSection\":[\"Recent News\"],\"inLanguage\":\"de-DE\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/derm-biomepharmaceuticals.com\/derm-biome-pharmaceuticals-inc-reports-positive-results-from-a-preclinical-study-in-atopic-dermatitis-its-new-generation-of-compounds-are-significantly-more-effective-than-fda-approved-topical-ad-d\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/derm-biomepharmaceuticals.com\/derm-biome-pharmaceuticals-inc-reports-positive-results-from-a-preclinical-study-in-atopic-dermatitis-its-new-generation-of-compounds-are-significantly-more-effective-than-fda-approved-topical-ad-d\/\",\"url\":\"https:\/\/derm-biomepharmaceuticals.com\/derm-biome-pharmaceuticals-inc-reports-positive-results-from-a-preclinical-study-in-atopic-dermatitis-its-new-generation-of-compounds-are-significantly-more-effective-than-fda-approved-topical-ad-d\/\",\"name\":\"Derm-Biome Pharmaceuticals, Inc. reports Positive Results from a Preclinical Study in Atopic Dermatitis: its new generation of compounds are significantly more effective than FDA-approved topical AD drug crisaborole - Derm-Biome Pharmaceuticals Inc.\",\"isPartOf\":{\"@id\":\"https:\/\/derm-biomepharmaceuticals.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/derm-biomepharmaceuticals.com\/derm-biome-pharmaceuticals-inc-reports-positive-results-from-a-preclinical-study-in-atopic-dermatitis-its-new-generation-of-compounds-are-significantly-more-effective-than-fda-approved-topical-ad-d\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/derm-biomepharmaceuticals.com\/derm-biome-pharmaceuticals-inc-reports-positive-results-from-a-preclinical-study-in-atopic-dermatitis-its-new-generation-of-compounds-are-significantly-more-effective-than-fda-approved-topical-ad-d\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/derm-biomepharmaceuticals.com\/wp-content\/uploads\/2021\/09\/announcement-2021-sept.jpg\",\"datePublished\":\"2021-09-16T15:28:51+00:00\",\"dateModified\":\"2021-09-16T15:32:30+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/derm-biomepharmaceuticals.com\/derm-biome-pharmaceuticals-inc-reports-positive-results-from-a-preclinical-study-in-atopic-dermatitis-its-new-generation-of-compounds-are-significantly-more-effective-than-fda-approved-topical-ad-d\/#breadcrumb\"},\"inLanguage\":\"de-DE\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/derm-biomepharmaceuticals.com\/derm-biome-pharmaceuticals-inc-reports-positive-results-from-a-preclinical-study-in-atopic-dermatitis-its-new-generation-of-compounds-are-significantly-more-effective-than-fda-approved-topical-ad-d\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"de-DE\",\"@id\":\"https:\/\/derm-biomepharmaceuticals.com\/derm-biome-pharmaceuticals-inc-reports-positive-results-from-a-preclinical-study-in-atopic-dermatitis-its-new-generation-of-compounds-are-significantly-more-effective-than-fda-approved-topical-ad-d\/#primaryimage\",\"url\":\"https:\/\/derm-biomepharmaceuticals.com\/wp-content\/uploads\/2021\/09\/announcement-2021-sept.jpg\",\"contentUrl\":\"https:\/\/derm-biomepharmaceuticals.com\/wp-content\/uploads\/2021\/09\/announcement-2021-sept.jpg\",\"width\":1000,\"height\":539},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/derm-biomepharmaceuticals.com\/derm-biome-pharmaceuticals-inc-reports-positive-results-from-a-preclinical-study-in-atopic-dermatitis-its-new-generation-of-compounds-are-significantly-more-effective-than-fda-approved-topical-ad-d\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/derm-biomepharmaceuticals.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Derm-Biome Pharmaceuticals, Inc. reports Positive Results from a Preclinical Study in Atopic Dermatitis: its new generation of compounds are significantly more effective than FDA-approved topical AD drug crisaborole\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/derm-biomepharmaceuticals.com\/#website\",\"url\":\"https:\/\/derm-biomepharmaceuticals.com\/\",\"name\":\"Derm-Biome Pharmaceuticals Inc.\",\"description\":\"Startup Biopharmaceutical Company\",\"publisher\":{\"@id\":\"https:\/\/derm-biomepharmaceuticals.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/derm-biomepharmaceuticals.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"de-DE\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/derm-biomepharmaceuticals.com\/#organization\",\"name\":\"Derm-Biome Pharmaceuticals\",\"url\":\"https:\/\/derm-biomepharmaceuticals.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"de-DE\",\"@id\":\"https:\/\/derm-biomepharmaceuticals.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/derm-biomepharmaceuticals.com\/wp-content\/uploads\/2019\/01\/Derm-Biome-Pharmaceuticals-white-1.png\",\"contentUrl\":\"https:\/\/derm-biomepharmaceuticals.com\/wp-content\/uploads\/2019\/01\/Derm-Biome-Pharmaceuticals-white-1.png\",\"width\":450,\"height\":200,\"caption\":\"Derm-Biome Pharmaceuticals\"},\"image\":{\"@id\":\"https:\/\/derm-biomepharmaceuticals.com\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/derm-biomepharmaceuticals.com\/#\/schema\/person\/7fd946a95040e8683129145f79976d8d\",\"name\":\"Derm-Biome Admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"de-DE\",\"@id\":\"https:\/\/derm-biomepharmaceuticals.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/010b14acf7a9fd5e8fbbc766302fccb7?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/010b14acf7a9fd5e8fbbc766302fccb7?s=96&d=mm&r=g\",\"caption\":\"Derm-Biome Admin\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Derm-Biome Pharmaceuticals, Inc. reports Positive Results from a Preclinical Study in Atopic Dermatitis: its new generation of compounds are significantly more effective than FDA-approved topical AD drug crisaborole - Derm-Biome Pharmaceuticals Inc.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/derm-biomepharmaceuticals.com\/de_de_formal\/derm-biome-pharmaceuticals-inc-reports-positive-results-from-a-preclinical-study-in-atopic-dermatitis-its-new-generation-of-compounds-are-significantly-more-effective-than-fda-approved-topical-ad-d\/","og_locale":"de_DE","og_type":"article","og_title":"Derm-Biome Pharmaceuticals, Inc. reports Positive Results from a Preclinical Study in Atopic Dermatitis: its new generation of compounds are significantly more effective than FDA-approved topical AD drug crisaborole - Derm-Biome Pharmaceuticals Inc.","og_description":"...","og_url":"https:\/\/derm-biomepharmaceuticals.com\/de_de_formal\/derm-biome-pharmaceuticals-inc-reports-positive-results-from-a-preclinical-study-in-atopic-dermatitis-its-new-generation-of-compounds-are-significantly-more-effective-than-fda-approved-topical-ad-d\/","og_site_name":"Derm-Biome Pharmaceuticals Inc.","article_published_time":"2021-09-16T15:28:51+00:00","article_modified_time":"2021-09-16T15:32:30+00:00","og_image":[{"width":1000,"height":539,"url":"https:\/\/derm-biomepharmaceuticals.com\/wp-content\/uploads\/2021\/09\/announcement-2021-sept.jpg","type":"image\/jpeg"}],"author":"Derm-Biome Admin","twitter_card":"summary_large_image","twitter_misc":{"Geschrieben von":"Derm-Biome Admin","Gesch\u00e4tzte Lesezeit":"2 Minuten"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/derm-biomepharmaceuticals.com\/derm-biome-pharmaceuticals-inc-reports-positive-results-from-a-preclinical-study-in-atopic-dermatitis-its-new-generation-of-compounds-are-significantly-more-effective-than-fda-approved-topical-ad-d\/#article","isPartOf":{"@id":"https:\/\/derm-biomepharmaceuticals.com\/derm-biome-pharmaceuticals-inc-reports-positive-results-from-a-preclinical-study-in-atopic-dermatitis-its-new-generation-of-compounds-are-significantly-more-effective-than-fda-approved-topical-ad-d\/"},"author":{"name":"Derm-Biome Admin","@id":"https:\/\/derm-biomepharmaceuticals.com\/#\/schema\/person\/7fd946a95040e8683129145f79976d8d"},"headline":"Derm-Biome Pharmaceuticals, Inc. reports Positive Results from a Preclinical Study in Atopic Dermatitis: its new generation of compounds are significantly more effective than FDA-approved topical AD drug crisaborole","datePublished":"2021-09-16T15:28:51+00:00","dateModified":"2021-09-16T15:32:30+00:00","mainEntityOfPage":{"@id":"https:\/\/derm-biomepharmaceuticals.com\/derm-biome-pharmaceuticals-inc-reports-positive-results-from-a-preclinical-study-in-atopic-dermatitis-its-new-generation-of-compounds-are-significantly-more-effective-than-fda-approved-topical-ad-d\/"},"wordCount":450,"commentCount":0,"publisher":{"@id":"https:\/\/derm-biomepharmaceuticals.com\/#organization"},"image":{"@id":"https:\/\/derm-biomepharmaceuticals.com\/derm-biome-pharmaceuticals-inc-reports-positive-results-from-a-preclinical-study-in-atopic-dermatitis-its-new-generation-of-compounds-are-significantly-more-effective-than-fda-approved-topical-ad-d\/#primaryimage"},"thumbnailUrl":"https:\/\/derm-biomepharmaceuticals.com\/wp-content\/uploads\/2021\/09\/announcement-2021-sept.jpg","articleSection":["Recent News"],"inLanguage":"de-DE","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/derm-biomepharmaceuticals.com\/derm-biome-pharmaceuticals-inc-reports-positive-results-from-a-preclinical-study-in-atopic-dermatitis-its-new-generation-of-compounds-are-significantly-more-effective-than-fda-approved-topical-ad-d\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/derm-biomepharmaceuticals.com\/derm-biome-pharmaceuticals-inc-reports-positive-results-from-a-preclinical-study-in-atopic-dermatitis-its-new-generation-of-compounds-are-significantly-more-effective-than-fda-approved-topical-ad-d\/","url":"https:\/\/derm-biomepharmaceuticals.com\/derm-biome-pharmaceuticals-inc-reports-positive-results-from-a-preclinical-study-in-atopic-dermatitis-its-new-generation-of-compounds-are-significantly-more-effective-than-fda-approved-topical-ad-d\/","name":"Derm-Biome Pharmaceuticals, Inc. reports Positive Results from a Preclinical Study in Atopic Dermatitis: its new generation of compounds are significantly more effective than FDA-approved topical AD drug crisaborole - Derm-Biome Pharmaceuticals Inc.","isPartOf":{"@id":"https:\/\/derm-biomepharmaceuticals.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/derm-biomepharmaceuticals.com\/derm-biome-pharmaceuticals-inc-reports-positive-results-from-a-preclinical-study-in-atopic-dermatitis-its-new-generation-of-compounds-are-significantly-more-effective-than-fda-approved-topical-ad-d\/#primaryimage"},"image":{"@id":"https:\/\/derm-biomepharmaceuticals.com\/derm-biome-pharmaceuticals-inc-reports-positive-results-from-a-preclinical-study-in-atopic-dermatitis-its-new-generation-of-compounds-are-significantly-more-effective-than-fda-approved-topical-ad-d\/#primaryimage"},"thumbnailUrl":"https:\/\/derm-biomepharmaceuticals.com\/wp-content\/uploads\/2021\/09\/announcement-2021-sept.jpg","datePublished":"2021-09-16T15:28:51+00:00","dateModified":"2021-09-16T15:32:30+00:00","breadcrumb":{"@id":"https:\/\/derm-biomepharmaceuticals.com\/derm-biome-pharmaceuticals-inc-reports-positive-results-from-a-preclinical-study-in-atopic-dermatitis-its-new-generation-of-compounds-are-significantly-more-effective-than-fda-approved-topical-ad-d\/#breadcrumb"},"inLanguage":"de-DE","potentialAction":[{"@type":"ReadAction","target":["https:\/\/derm-biomepharmaceuticals.com\/derm-biome-pharmaceuticals-inc-reports-positive-results-from-a-preclinical-study-in-atopic-dermatitis-its-new-generation-of-compounds-are-significantly-more-effective-than-fda-approved-topical-ad-d\/"]}]},{"@type":"ImageObject","inLanguage":"de-DE","@id":"https:\/\/derm-biomepharmaceuticals.com\/derm-biome-pharmaceuticals-inc-reports-positive-results-from-a-preclinical-study-in-atopic-dermatitis-its-new-generation-of-compounds-are-significantly-more-effective-than-fda-approved-topical-ad-d\/#primaryimage","url":"https:\/\/derm-biomepharmaceuticals.com\/wp-content\/uploads\/2021\/09\/announcement-2021-sept.jpg","contentUrl":"https:\/\/derm-biomepharmaceuticals.com\/wp-content\/uploads\/2021\/09\/announcement-2021-sept.jpg","width":1000,"height":539},{"@type":"BreadcrumbList","@id":"https:\/\/derm-biomepharmaceuticals.com\/derm-biome-pharmaceuticals-inc-reports-positive-results-from-a-preclinical-study-in-atopic-dermatitis-its-new-generation-of-compounds-are-significantly-more-effective-than-fda-approved-topical-ad-d\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/derm-biomepharmaceuticals.com\/"},{"@type":"ListItem","position":2,"name":"Derm-Biome Pharmaceuticals, Inc. reports Positive Results from a Preclinical Study in Atopic Dermatitis: its new generation of compounds are significantly more effective than FDA-approved topical AD drug crisaborole"}]},{"@type":"WebSite","@id":"https:\/\/derm-biomepharmaceuticals.com\/#website","url":"https:\/\/derm-biomepharmaceuticals.com\/","name":"Derm-Biome Pharmaceuticals Inc.","description":"Startup Biopharmaceutical Company","publisher":{"@id":"https:\/\/derm-biomepharmaceuticals.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/derm-biomepharmaceuticals.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"de-DE"},{"@type":"Organization","@id":"https:\/\/derm-biomepharmaceuticals.com\/#organization","name":"Derm-Biome Pharmaceuticals","url":"https:\/\/derm-biomepharmaceuticals.com\/","logo":{"@type":"ImageObject","inLanguage":"de-DE","@id":"https:\/\/derm-biomepharmaceuticals.com\/#\/schema\/logo\/image\/","url":"https:\/\/derm-biomepharmaceuticals.com\/wp-content\/uploads\/2019\/01\/Derm-Biome-Pharmaceuticals-white-1.png","contentUrl":"https:\/\/derm-biomepharmaceuticals.com\/wp-content\/uploads\/2019\/01\/Derm-Biome-Pharmaceuticals-white-1.png","width":450,"height":200,"caption":"Derm-Biome Pharmaceuticals"},"image":{"@id":"https:\/\/derm-biomepharmaceuticals.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/derm-biomepharmaceuticals.com\/#\/schema\/person\/7fd946a95040e8683129145f79976d8d","name":"Derm-Biome Admin","image":{"@type":"ImageObject","inLanguage":"de-DE","@id":"https:\/\/derm-biomepharmaceuticals.com\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/010b14acf7a9fd5e8fbbc766302fccb7?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/010b14acf7a9fd5e8fbbc766302fccb7?s=96&d=mm&r=g","caption":"Derm-Biome Admin"}}]}},"_links":{"self":[{"href":"https:\/\/derm-biomepharmaceuticals.com\/de_de_formal\/wp-json\/wp\/v2\/posts\/406"}],"collection":[{"href":"https:\/\/derm-biomepharmaceuticals.com\/de_de_formal\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/derm-biomepharmaceuticals.com\/de_de_formal\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/derm-biomepharmaceuticals.com\/de_de_formal\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/derm-biomepharmaceuticals.com\/de_de_formal\/wp-json\/wp\/v2\/comments?post=406"}],"version-history":[{"count":2,"href":"https:\/\/derm-biomepharmaceuticals.com\/de_de_formal\/wp-json\/wp\/v2\/posts\/406\/revisions"}],"predecessor-version":[{"id":410,"href":"https:\/\/derm-biomepharmaceuticals.com\/de_de_formal\/wp-json\/wp\/v2\/posts\/406\/revisions\/410"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/derm-biomepharmaceuticals.com\/de_de_formal\/wp-json\/wp\/v2\/media\/408"}],"wp:attachment":[{"href":"https:\/\/derm-biomepharmaceuticals.com\/de_de_formal\/wp-json\/wp\/v2\/media?parent=406"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/derm-biomepharmaceuticals.com\/de_de_formal\/wp-json\/wp\/v2\/categories?post=406"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/derm-biomepharmaceuticals.com\/de_de_formal\/wp-json\/wp\/v2\/tags?post=406"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}